MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
"Triple Helix" Innovation Model
4. Triple Helix _ Capture Strategies
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: Ireland
Bristol-Myers Squibb Company (NYSE:BMY)
Finance & Acquisitions: Bristol Myers Squibb
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
Organization & Developments: Mirati
Parents
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
Children
*Mirati Therapeutics is developing treatments for patients with cancer by targeting the genetic changes in tumor cells that result in uncontrolled tumor growth and spread.
*Mirati Therapeutics is presenting preliminary results from a clinical trial of MRTX849, a pill designed to block the “undruggable” cancer protein called KRAS
*Their precision oncology strategy seeks to treat the patients most likely to benefit and is driven by 1) drugs that target very specific genetic mutations that cause cancer, and 2) genomic tests that identify patients who carry those driver mutations.
2017: Mirati Therapeutics: Is This $5 Busted IPO A Buy, Sell, Or Hold? - Mirati Therapeutics, Inc. (NASDAQ:MRTX)
2018: 2 Small Biotechs To Consider - Mirati Therapeutics (MRTX)
2018: Mirati Therapeutics_Revisiting A 'Busted IPO' Rocket_seekingalpha.com
2019: Mirati Therapeutics: Revisiting As KRAS Data Nears_seekingalpha.com
2019: Mirati Therapeutics: Updates To Thesis, ASCO Winner Sans Data_seekingalpha.com
2019: Mirati: Brewing A Knock Out Combo Against Cancers_seekingalpha.com
2020: Mirati Therapeutics: A Gift That Keeps On Giving
2020: Mirati Therapeutics: Paying $220 A Share Sounds Excessive But Cracking KRAS Is A Big Deal
2020: Mirati Will Continue To Shine As It Keeps Delivering Promising Results
2021: Mirati Therapeutics: Another Growth Cycle Approaching
2021: Mirati: Running On Good Science And A Lot Of Enthusiasm
2021: Why Mirati Therapeutics Is A Dangerous Rival To Amgen In Colon Cancer
2022: Amgen Vs. Mirati: Playing To Win In KRAS Mutated Lung Cancer_seekingalpha.com
2022: Mirati Challenges Amgen in KRAS Space with FDA Accelerated Approval
2022: Mirati Plunges as Lung Cancer Studies Disappoint Wall Street_ Bloomberg
2022: Mirati Therapeutics: Is There A Big Pharma Buyout In Play And What's The Price Tag?_ seekingalpha.com
2022: Mirati Therapeutics: Poised For Takeoff_ seekingalpha.com
2022: Mirati: A Potential Blockbuster Stock, Will Need Patience_
2023: Evaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisition_seekingalpha.com
2023: Mirati Therapeutics: Anatomy Of A Long Simmering Buyout
Jumps
*Key People: Mirati
Finance & Acquisitions: Mirati